Lancet

History

2022

Start of warehouse in Podolsk district

On February 8, 2022, it became known that the national supplier of medicines, one of the representatives of the budget segment of the pharmaceutical market of Russia JSC Lancet, opened a new warehouse in the Podolsky district. Moscow area

The storage conditions for medicines in stock comply with the international distribution standards GDP (Good Distribution Practices). According to representatives of JSC Lancet, compliance was confirmed by an external audit by foreign suppliers of the company.

The new pharmaceutical warehouse will allow the company not only to increase the storage volumes of drugs, but also to increase the speed of processing orders by five times, which is especially important in the context of a pandemic and constantly changing demand dynamics.

"The increase in storage capacity allows us to form long-term safe inventories to offset possible interruptions in supply chains, to provide patients with innovative life-saving drugs even more quickly," said Anton Zybin, general director of Lancet JSC.

JSC "Lancet" carried out the first delivery abroad

In January 2022, it was announced that Lancet had completed the first shipment of medicines to Georgia. Georgian partners within the framework of the concluded contract received medical sponges "Tahokomb," which are used in surgery to prevent blood loss. This was the first experience of such foreign cooperation for the company.

For many Western manufacturers, the local pharmaceutical market in Central Asia and Transcaucasia is of limited interest due to its small capacity. In addition, generics are popular in these markets, which have a notoriously lower cost and cost less than original medicines. Therefore, the function of drug suppliers in these countries was taken over by several Russian companies, including now Lancet JSC.

"We set ourselves the goal in 2022 to establish contact with local markets, with local distributors, and adapt our work to their needs. We believe that patients in these countries should also be able to purchase high-quality and effective drugs. This is the mission of our company, "commented Anton Zybin, General Director of Lancet JSC

"The goal of our company is to understand and summarize the needs of each market of a particular country in order to add them to certain therapeutic directions in the future. I.e. doctors or hospital administrators will be offered a certain group of drugs from various manufacturers, for example, for anesthesiology and resuscitation or the treatment of cancer. Thus, we will close several needs of clinics at once and fulfill our mission to provide patients in these countries with the necessary medicines, "commented Natalia Kapranova, Director of Business Development of Lancet JSC.

It is expected that by 2025, in the territory of the EAEU countries (to date, five states are united - the Republic of Armenia, the Republic of Belarus, the Republic of Kazakhstan, the Kyrgyz Republic and the Russian Federation), all rules for the production and sale of pharmaceuticals and medical products will be unified, and manufacturers will be obliged to comply with them. As a result, the quantity of goods brought to the territory of states illegally (gray imports) should be reduced, as well as administrative barriers to access of medical drugs to national markets.

2021: JSC "Lancet" strengthened leadership in the supply to the Russian market of anticoagulants and drugs for anesthesiology and resuscitation

JSC Lancet increased sales of blood management drugs, including anticoagulants, by more than 20%, and drugs for anesthesiology and resuscitation by 7.4% for 9 months of 2021 compared to the same period in 2020 and strengthened its leadership in the Russian market in these areas.

In the context of the ongoing COVID-19 epidemic in the Russian pharmaceutical market, there is an increase in demand for anticoagulants and drugs for anesthesiology and resuscitation. Analysts of the Lancet pharmaceutical company note a tendency to increase sales in these two areas.

In 2021, anticoagulants reached their maximum sales volume on the Russian market over the past three years, in the first half of 2021 alone, drug sales increased by 9% compared to the same period in 2020. Active growth in demand for drugs for anesthesiology and resuscitation was expected to occur in 2020, and is now in positive dynamics - there is an increase of 5%.

"At the beginning of 2020, when there was an explosive growth in anticoagulants and drugs for anesthesiology and resuscitation, which is associated with the influence of the COVID-19 virus on the circulatory system, all the world's largest manufacturers of these drugs were not ready to meet the demand," said Anton Zybin, general director of Lancet JSC. "Given our sustained partnership with manufacturers, we have been able to agree on the inclusion of Russia in the list of priority countries and provide our healthcare system with the necessary volumes of anticoagulants and drugs for anesthesiology and resuscitation."

An additional incentive to increase sales of anticoagulants from January 2020 was the start of a program for the secondary prevention of cardiovascular diseases, aimed at reducing mortality from cardiovascular diseases and increasing average life expectancy.

"We are seeing a steady increase in demand for anticoagulants and drugs for anesthesiology and resuscitation, which is not surprising. Unfortunately, this is primarily due to the continued spread of COVID-19 coronovirus. It is encouraging that the Ministry of Health is taking all necessary measures to provide medical institutions with the necessary medicines, "says Irina Kovalchuk, Deputy General Director of Lancet JSC

The main factor that influenced the growth of the Russian pharmaceutical market in 2020-21 is the COVID-19 pandemic. Pharmacotrasl showed growth even higher than predicted earlier this year. According to Lancet JSC, the total volume of the state segment of the pharmaceutical market from January to September 2021, amounted to 555 billion rubles, for comparison - in 2020 in the same period, the figure was 451 billion rubles.